| Expression pattern: |
UP |
| Associated gene: |
MT2A, Ago2 |
| Associated microRNA: |
miR-296-3p |
| Biological function: |
circEIF6 promotes aerobic glycolysis, angiogenesis, proliferation, and malignant progression in TNBC cells; circEIF6 knockdown suppresses glycolysis, angiogenesis, proliferation, migration/invasion-related malignant phenotype and increases apoptosis-associated suppression of malignancy through the miR-296-3p/MT2A pathway. |
| Molecular mechanism: |
circEIF6 acts as a competing endogenous RNA that sponges miR-296-3p and regulates MT2A expression, thereby promoting aerobic glycolysis and angiogenesis in TNBC. |
| Biological pathway or process: |
glycolysis (promotes); angiogenesis (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; RNA Pull-Down; Transfection; MTT; Transwell Assay; Annexin V/PI Flow Cytometry; Tube Formation Assay; Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
circEIF6 upregulation correlates with advanced TNM stage, tumor size, metastasis and poor prognosis; elevated circEIF6 levels were associated with poorer overall survival and may represent a novel diagnostic marker for TNBC. |
| Description: |
circEIF6 is upregulated in TNBC tissues and MDA-MB-231 cells and is associated with advanced clinicopathological features and poor overall survival. Mechanistically, circEIF6 acts as a ceRNA for miR-296-3p to regulate MT2A, promoting aerobic glycolysis, angiogenesis, proliferation and malignant progression, suggesting potential diagnostic and therapeutic value in TNBC. |
| Confidence score: |
0.8709 |